Definitive Contract 75N91018C00041
Award Date
9/13/18
Potential Completion Date
6/16/19
Potential Value
$300K
Federal Agency
National Cancer Institute
Awardee
Avantgen Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Pablo, CA, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $747,441.00 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute to Avantgen Inc., a small business based in San Diego, CA. The contract is for a Small Business Innovation Research (SBIR) Phase II project titled "Recombinant Antibodies as Affinity Captures" under Topic 288. The goal is to develop recombinant antibodies for use in affinity capture applications. This contract builds upon Avantgen's prior SBIR Phase I and II awards from the National...
This is a Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Vetigenics LLC, a woman-owned small business. The contract, valued at $1,999,381.00, is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under the MOONSHOT research program, Topic 372. The contract has a completion date of February 15, 2025 and is set aside for small businesses. No subcontractor...
This is a $999,996.00 definitive Cost Plus Fixed Fee contract awarded by the National Cancer Institute, a civilian agency, to Avantgen Inc., a small business based in San Diego, California. The contract is for the development of recombinant rabbit monoclonal antibodies as affinity captures for peptides. Avantgen previously received other federal contracts and grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and National Cancer Institute for...
This is a $1,995,852.00 Firm Fixed Price SBIR Phase II contract awarded by the National Cancer Institute (NCI) to Avantgen Inc., a small business based in San Diego, California. The contract is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under Topic 372. The goal is to develop high-affinity, highly specific rabbit monoclonal antibodies against an expanded panel of 26 canine biomarkers to facilitate the use of dogs...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Synbal, Inc., a small business located in La Costa, California. The contract, valued at $2,300,000.00, is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under the "MOONSHOT" initiative. The contract was set aside for small businesses...
This is a $356,021 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies for ferret biomarkers. This work is set aside for small businesses. Avantgen has previously received NIH contracts to develop rapid diagnostic...
<p>This is a $1,999,386.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Avoneaux Medical Institute, LLC, a veteran-owned limited liability company. The contract is for the development of spatial micropurification technology under SBIR Topic 403. The contract is a definitive, firm fixed-price contract with a period of performance ending on September 18, 2024.</p>
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase 2 contract worth $299,920.00 to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business in Cambridge, MA. The contract, which is a definitive, firm-fixed-price contract, supports SBIR Topic 314 and has an ultimate completion date of October 21, 2016. The contract is set aside for total small business participation.</p>